Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
24.06. | Jin Medical International ernennt Dr. James Jiayuan Tong zum unabhängigen Direktor | 6 | Investing.com Deutsch | ||
JIN MEDICAL INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
24.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
17.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
06.05. | Jin Medical International Ltd. - Nasdaq Minimum Bid Price Non-Compliance | 40 | GlobeNewswire (Europe) | Changzhou City, China, May 06, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ: ZJYL) (the "Company") today announced that on May 2, 2025, it received a deficiency letter (the "Notice")... ► Artikel lesen | |
25.04. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
24.01. | Jin Medical International Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,098 | -3,92 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
PLUS THERAPEUTICS | 0,346 | -1,54 % | Plus Therapeutics Inc.: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases | HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,791 | -0,88 % | Atossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines... ► Artikel lesen | |
PING AN HEALTHCARE | 1,023 | +0,44 % | PA GOODDOCTOR (01833): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | ||
CO-DIAGNOSTICS | 0,210 | -0,94 % | Co-Diagnostics, Inc. - 8-K, Current Report | ||
CYTOSORBENTS | 0,904 | -0,77 % | Cytosorbents Corp: CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR | PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions... ► Artikel lesen | |
VERU | 0,499 | -2,65 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
AMBU | 13,120 | +1,71 % | Ambu A/S: Interim Report For Q2 2024/25 And The Half-year | 7.5.2025 07:00:01 CEST | Ambu A/S |
Half Year financial report
In the second quarter of the 2024/25 financial year, Ambu delivered 11.7% organic revenue growth and a 14.4% EBIT margin before special... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
VOLITIONRX | 0,662 | -2,49 % | VolitionRx - Nu.Q advances in lung cancer management | Despite rapid advancements in cancer treatments, effective diagnostics for early screening and disease monitoring continue to be an unmet need. This is felt acutely in lung cancer, which is the leading... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,080 | -3,70 % | Aktien Frankfurt Ausblick: Dax moderat höher erwartet - Drohende Zölle im Fokus | FRANKFURT (dpa-AFX) - Der Dax steuert nach der mäßigen Vorwoche am Montag auf eine freundliche Eröffnung zu. Allerdings dürfte die nahende Deadline für eine Lösung des Handelskonflikts zwischen den... ► Artikel lesen | |
FRESENIUS | 41,940 | -0,66 % | Schock-News für Fresenius Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
FRESENIUS MEDICAL CARE | 46,260 | -1,45 % | EQS-PVR: Fresenius Medical Care AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius Medical Care AG
Fresenius Medical Care AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
10.07.2025... ► Artikel lesen | |
GERRESHEIMER | 49,020 | -2,93 % | BARCLAYS stuft GERRESHEIMER AG auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Gerresheimer von 67 auf 64 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. Analyst Gaurav Jain rechnet... ► Artikel lesen | |
CARL ZEISS MEDITEC | 52,05 | -1,79 % | Carl Zeiss Meditec Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! |